These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 25639313)

  • 21. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
    Yamamoto M; Nakao T; Ogawa W; Fukuoka H
    Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.
    Truong HL; Nellesen D; Ludlam WH; Neary MP
    J Med Econ; 2014 Apr; 17(4):288-95. PubMed ID: 24617917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical management of Cushing's disease: what is the future?
    Fleseriu M; Petersenn S
    Pituitary; 2012 Sep; 15(3):330-41. PubMed ID: 22674211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
    Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER
    Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.
    Serban AL; Zampetti B; Saladino A; Favero V; Chiodini I; Cozzi R
    Endocr Metab Immune Disord Drug Targets; 2024; 24(7):845-849. PubMed ID: 37937561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cushing's disease: pathobiology, diagnosis, and management.
    Lonser RR; Nieman L; Oldfield EH
    J Neurosurg; 2017 Feb; 126(2):404-417. PubMed ID: 27104844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
    Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
    J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current approaches to the pharmacological management of Cushing's disease.
    Molitch ME
    Mol Cell Endocrinol; 2015 Jun; 408():185-9. PubMed ID: 25450859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Cushing's disease: a mechanistic update.
    Cuevas-Ramos D; Fleseriu M
    J Endocrinol; 2014 Nov; 223(2):R19-39. PubMed ID: 25134660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
    Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
    Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cushing's disease.
    Bertagna X; Guignat L; Groussin L; Bertherat J
    Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):607-23. PubMed ID: 19945026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
    Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
    Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical management of Cushing's disease.
    Tritos NA; Biller BM
    J Neurooncol; 2014 May; 117(3):407-14. PubMed ID: 24146187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical combination therapies in Cushing's disease.
    Vilar L; Naves LA; Machado MC; Bronstein MD
    Pituitary; 2015 Apr; 18(2):253-62. PubMed ID: 25647330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bilateral adrenalectomy in the treatment of refractory Cushing's disease.
    Wong A; Eloy JA; Liu JK
    Neurosurg Focus; 2015 Feb; 38(2):E9. PubMed ID: 25639327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.
    Seltzer J; Ashton CE; Scotton TC; Pangal D; Carmichael JD; Zada G
    Neurosurg Focus; 2015 Feb; 38(2):E17. PubMed ID: 25639319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
    Cohan P
    Endocr Pract; 2014 Jan; 20(1):84-93. PubMed ID: 24126229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.